Price$5.90-0.19 (-3.12%)
01:30 PM07:45 PM
News · 26 weeks49-14%
2025-10-262026-04-19
Mix2890d
- Other11(39%)
- Insider8(29%)
- SEC Filings6(21%)
- Earnings2(7%)
- Leadership1(4%)
Latest news
25 items- PRPersonalis to Announce First Quarter 2026 Financial ResultsPersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly
- PRPersonalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026Podium presentation on NeXT Personal® monitoring neoadjuvant therapy in colorectal cancer; Real-world data from 10,000 patients reinforce industry-leading sensitivity; Data presented for a new NeXT Personal feature for monitoring resistance mutations Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence
- PRPersonalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026Oral podium presentation to highlight NeXT Personal® in colorectal cancer; Personalis to debut first data for Real-Time Variant Tracker™ to monitor therapy resistance during NeXT Personal MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company's NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 17-22, 2026, in San Diego, California. A focus of this year's data is the introduction of a new NeXT Personal MRD test option, Real-Time Variant Tracker, a
- SECSEC Form DEFA14A filed by Personalis Inc.DEFA14A - Personalis, Inc. (0001527753) (Filer)
- SECSEC Form DEF 14A filed by Personalis Inc.DEF 14A - Personalis, Inc. (0001527753) (Filer)
- PRPersonalis to Participate in the 25th Annual Needham Virtual ConferencePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at
- INSIDERCFO AND COO Tachibana Aaron was granted 34,375 shares, increasing direct ownership by 21% to 198,833 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERSVP and Chief Legal Officer Moore Stephen Michael was granted 28,125 shares, increasing direct ownership by 44% to 92,325 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERChief Executive Officer Hall Christopher M was granted 87,500 shares, increasing direct ownership by 59% to 235,986 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERPresident and CMO Chen Richard was granted 46,875 shares, increasing direct ownership by 37% to 173,880 units (SEC Form 4)4 - Personalis, Inc. (0001527753) (Issuer)
- SECSEC Form 8-K filed by Personalis Inc.8-K - Personalis, Inc. (0001527753) (Filer)
- PRPersonalis Appoints Dr. Richard Chen as President to Further Accelerate MRD AdoptionDr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific l
- PRPersonalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease," showed that ultrasensitive molecular residual disease (MRD) testing with NeXT Personal can perform better than current standard approaches in predicting patient outcomes following neoadjuvant therapy (NAT). The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across more than 24 leading U
- SECSEC Form S-8 filed by Personalis Inc.S-8 - Personalis, Inc. (0001527753) (Filer)
- SECSEC Form 10-K filed by Personalis Inc.10-K - Personalis, Inc. (0001527753) (Filer)
- SECPersonalis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Personalis, Inc. (0001527753) (Filer)
- PRPersonalis Reports Fourth Quarter and Full Year 2025 Results and Recent HighlightsClinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology Strong cash position of approximately $240 million provides capital for commercial expansion Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial
- INSIDERSEC Form 4 filed by CFO AND COO Tachibana Aaron4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF MEDICAL OFFICER AND EVP Chen Richard4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERSEC Form 4 filed by SVP and Chief Legal Officer Moore Stephen Michael4 - Personalis, Inc. (0001527753) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT AND CEO Hall Christopher M4 - Personalis, Inc. (0001527753) (Issuer)
- PRPersonalis to Participate in the TD Cowen 46th Annual Healthcare ConferencePersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at the Boston Marriott Copley Place in Boston, MA. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect mini
- SECSEC Form SCHEDULE 13G filed by Personalis Inc.SCHEDULE 13G - Personalis, Inc. (0001527753) (Subject)
- PRPersonalis to Announce Fourth Quarter and Full Year 2025 Financial ResultsPersonalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will
- PRPersonalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer SurveillanceLung cancer coverage, supported by data from the landmark TRACERx collaboration, follows recent approval in breast cancer, providing access to Medicare patients. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular residual disease (MRD) test for surveillance of patients with Stage I to III non-small cell lung cancer (NSCLC). This coverage determination is grounded in clinical evidence generated through the company's collaboration with the TRACERx (TRAcking Cancer Evolution through therapy (Rx)) consortium. Data from this world-renowned longitudinal study, recently published in C